Johnson & Johnson (JNJ) is exploring a bid to acquire Intra-Cellular Therapies (ITCI), a biopharmaceutical company focused on treatments for central nervous system disorders, Bloomberg’s Michelle Davis and Dinesh Nair report, citing people familiar with the matter. Deliberations are ongoing and there’s no certainty Johnson & Johnson will decide to pursue a deal, the people said. Other suitors could also emerge, they said.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular price target raised to $118 from $100 at BofA
- Venu Sports JV discontinued, Walgreens reports Q1 beat: Morning Buzz
- Intra-Cellular settlement with Sandoz ‘clear positive,’ says JPMorgan
- RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement
- Intra-Cellular settles Caplyta patent litigation with Sandoz